Begin typing your search above and press return to search.
Volume: 20 Issue: 8 August 2022 - Supplement - 4

FULL TEXT

A Narrative Review COVID-19 in Solid-Organ Transplantation: Real-World Evidence From India

Worldwide, India ranks number 2 and 3 for COVID-19 burden and absolute transplant numbers, respectively. Here, we summarized our single and multicenter Indian studies on solid-organ transplant during the COVID-19 pandemic. During the pandemic, solid-organ transplants declined 40% to 50%. The mortality rate in COVID-19-positive kidney transplant recipients (11.6%) was lower in India compared with the developed world during the first wave and lower compared with maintenance hemodialysis patients (13% to 38%) but significantly higher compared with the nonimmunosuppressed general population (1% to 3%) in India. We contributed to National Organ and Tissue Transplant Organization transplant-related guidelines to increase safety and access to solid-organ transplant. We reported the safety and feasibility of remdesivir (n = 57) and convalescent plasma therapy (n = 10) in kidney transplant recipients. We reported 100% patient and graft survival without any complications related to COVID-19 in a large cohort of kidney transplant recipients who recovered from COVID-19 (n = 372) and a large cohort of kidney transplant recipients of living donors (n = 31) who recovered from COVID-19 without any change in induction and maintenance immunosuppression. COVID-19 disease severity and mortality in the second episode (reoccurring infection) was higher (46%) compared with the first episode (11.6%). There was 4.4% incidence of COVID-19-associated mucormycosis in kidney transplant recipients with mortality of 46% in the second wave. We reported COVID-19 vaccine safety with suboptimal efficacy in kidney transplant recipients and dialysis patients compared with the general population. Our report suggested that transplant with carefully selected COVID-19-recovered donors and patients may be feasible and safe, at least over the short term. Continued research is needed on vaccine efficacy, booster doses, and long-term followup sequelae.


Key words : Immunosuppression, Impact, Kidney transplant recipients, Pandemic

Introduction

Globally, as of April 14, 2022, there have been 500 186 525 confirmed cases of coronavirus disease (COVID-19), including 6 190 349 deaths, reported to the World Health Organization. In addition, as of April 13, 2022, a total of 11 294 502 059 SARS?CoV?2 vaccine doses have been administered worldwide. Solid-organ transplant (SOT) is an established risk factor for COVID-19-associated morbidity and mortality. Worldwide data1 have shown that the impact of COVID-19 on transplant volume has been unequal in various regions of the globe. Some nations have shown a marked decline in transplant numbers even with low-level impacts of the pandemic, and some nations have had a negligible impact compared with the higher overall mortality in their region. Developing nations had more struggles, as the level of health care workers and medical supplies emptied faster compared with the slow augmentation of medical facilities and recovery of cases. The pandemic led to a high diversion of medical services, and many transplant centers were transformed into dedicated COVID-19 centers.

Indian Scenario

The Indian subcontinent was the second worst-hit nation in the COVID-19 pandemic overall. Per the Ministry of Health and Family Welfare (MOHF),2 as of April 16, 2022, India has 11 366 (0.03%) active cases, 42 507 834 (98.76%) recovered cases, and 521 747 (1.21%) deaths. In addition, the total COVID-19 vaccination numbers reached 1 863 831 723. India posted nationwide, statelevel, and regional lockdowns at different times over the pandemic period. During the lockdown period, a survey of liver transplant centers3 demonstrated medical, social, and psychosocial impacts among the liver transplant recipients. Another survey4 of parents of pediatric liver transplant recipients showed knowledge gaps and areas of concern to be targeted during the pandemic. Accessing the real-world situation by survey in the pandemic assists in understanding both deficits in knowledge and requirements needed to change health policies for better management of the targeted population. Western literature on the effects of COVID-19 on transplant services and clinical outcomes are exclusive, and there are comparatively fewer reports from the Indian subcontinent, especially for heart and lung transplantation.

The primary purpose of this review article is to summarize the data published from Indian transplant centers, which would allow an excellent learning resource that describes the overview of the research and lagging areas in India. This would help in filling the knowledge gap and help in forming a focused approach in case of future waves of the pandemic.

Methods

We conducted a literature search through the search engines of EMBASE, MEDLINE, PubMed, Google Scholar, Scopus, and WHO portal for COVID-19. We used the following MeSH terms: COVID-19, SARS-CoV-2, solidorgan transplantation, kidney, pancreas, liver, heart, India. We included no filter for time of publication. There was no restriction on languages. For publication types, we excluded systematic reviews, meta-analyses, and editorials. We included relevant published research items, including guidelines, reviews, original articles, brief communication, commentaries, letter to editors, case reports, and case series. If full text was not available or not reported, that study was excluded from our review. Any research data coming from Indian centers that pertained to SOT were eligible for inclusion. Inclusion criteria involved all SOT data associated with COVID-19 from Indian centers, irrespective of the age of the SOT recipient or organ transplanted. Exclusion criteria involved studies on hemopoietic stem cell transplant or eye or tissue transplant. The authors HSM and VBK performed the literature search, and SC checked the authenticity and validity of the articles. Any confusion or discordance in the articles was resolved by group discussion among these authors.

Development of Transplant-Specific Guidelines During the COVID-19 Pandemic

False assumptions, knowledge gaps, diversified virus strains, diverse health care systems, resource limitations, and dilemmas on decision making were some of the reasons for worsening the situation in the first wave of the pandemic5; hence, consensus statements and evidencebased regularly upgraded guidelines were necessary to increase safety in patients care. During the first wave, the “Infodemic” was more pandemic than COVID-19. The National Organ and Tissue Transplant Organization (NOTTO), a national-level organization governing Indian activities of coordination and networking for procurement and distribution of organs and tissues and the registry of organs and tissues for donation and transplant, made a tremendous effort to publish guidelines6 for transplant professionals on COVID-19, starting from the first wave of the pandemic.7

The organization published vaccine guidelines for transplant professionals that stressed equity and priority of vaccines for SOT and patients on wait lists.8 The updated NOTTO guidelines for vaccination in SOT9 calls for prioritizing the SOT population for vaccination. Vaccination was not mandatory and is a voluntary process in India, and no patient can be removed from the waitlist if he or she is unvaccinated. However, those on the waitlist are counseled compulsorily for at least 1 dose before surgery. Similarly, for living donors, presurgery vaccination of both the donor and recipient is ideal, but failure for the same does not predispose them to delayed surgery. In Indian settings, currently, antibody response measurements are only for research purposes, and the booster dose is not specific to the SOT population. The vaccine-induced thrombotic thrombocytopenia (VITT)-specific NOTTO guidelines10 for vaccination for India urged on having a multispecialty collaboration for decision making in accepting or discarding a VITT donor.

The Indian Society of Organ Transplantation11 has provided guidelines for transplant for living donors and potential recipients who are recovering from COVID-19. The introductory goal of the recommendations was to ensure a COVID-19-free safe pathway for transplant, without compromising the outcomes of the donor or recipient who is recovering or has recovered from COVID-19. The Liver Transplant Society of India (LTSI)12 issued timely guidelines for safeguarding patients on waitlists and liver transplant recipients who are at high risk for mortality. They also published guidelines on emergent surgeries, minimally invasive strategies, hepatectomy, and isolation strategies. The LTSI also issued protocol guidelines for conducting pediatric liver transplant.13 The Indian Society of Heart and Lung Transplantation (ISHLT),14 which is the governing body for heart and lung transplant, has also published recommendations for patients and professionals involved in care in this area of transplantation. The key element of the ISHLT guidelines was normal highresolution computed tomography of the thorax before lung donation, which remained a prerequisite for the major part of the pandemic for SOT.

The Indian Society of Organ Transplantation, the LTSI, and the ISHLT together formulated guidelines for continuing deceased organ donation during the COVID-19 pandemic.15 Discarding or accepting an organ has ethical, moral, medical, and psycho-social aspects. These guidelines have given a solid framework for the basis of decisionmaking in all of these complex judgments and served as a guiding tool for the initial management and approach to the pandemic for transplant centers across the nation.

In brief, guidelines can only steer the path, but it becomes a pledging responsibility for the transplant programs16 to educate, support, and remain accessible to SOT groups of patients in pandemic times. The COVID-19 Working Group of Indian Society of Nephrology has reported guidance to improve safety during maintenance dialysis.17

Decline in Transplant Capacity and Volume During the Pandemic: An Unavoidable Situation

The overall COVID-19 burden was highest in the United States and India. In an analysis from the global observatory on organ donation and transplantation,18 transplant volume decreased in all regions of the world but more so in the developing than in the developed world. Developed nations like the United States were able to rebuild during the second wave after an initial drop in transplant volume during the first wave; this allowed their cumulative transplant numbers per year to remain less affected. However, nations like India suffered more, especially for less well-organized deceased donation programs.19,20 Because deceased donation is in the preliminary stages in India and continuation of elective transplant surgery would shrink the medical capacity and intensive care unit beds, which could be utilized during the pandemic, the temporary ceasing of elective transplant surgeries was expected in Indian settings.21

The impact on liver transplant volume was described in a trinational study,22 which included South Indian liver transplant centers. The study showed a significant decline in volume that was influenced by logistics, local and national regulatory policies, COVID-19 transmission state, and health care capacity. A single-center study that involved the largest public sector transplant hospital in India23 described the landscape of changing transplant volumes amid the pandemic during the first and second waves. In a multicenter study24 (n = 18) on the cumulative impact on kidney donation and nephrology practices, public sector hospitals were reported to be more affected than private transplant hospitals. Most (70% to 90%) of transplant services are available in private sector hospitals in India. The study also reported no increase in allograft biopsies or non-COVID-19 admissions, which subtly showed no longterm impact of COVID-19 infection in the context of graft function.

Pediatric liver transplant programs were shown to effectively continue in the absence of alternative medical therapies such as dialysis in patients with end-stage kidney disease, without many diversions of health care resources by using minimal medical capacity.25 Although living donor liver transplant (LDLT) procedures were reduced, a study showed that the pattern of referred patients shifted to those who were sicker.26 This shows that the logistics of a pandemic can be avoided by a better referral policy, as we make them stricter, with triaging of urgent procedures.

In a South Indian report, health policy changes to minimize COVID-19 infection had a potential added benefit of reducing other infections, leading to better outcomes27 This is important in developing nations like India, where infectious etiologies are responsible for mortality in posttransplant settings. This early report described that, after restructuring a COVID-19-free pathway, liver transplant outcomes were not affected by the pandemic per se. Another similar multicenter experience28 echoed the findings in liver transplant practices. Patients with decompensated liver failure and those with high Model for End-Stage Liver Disease scores were more likely to have irreversible outcomes if transplant services remain at a standstill. The selective recognition and surgery of such patients were shown in a report,29 which are the practiced recommendations from the LTSI.

In a study from North India,30 the incidence and outcomes of LDLT recipients and waitlisted patients were reported to be similar to the general population, and favorable outcomes of LDLT performed amid the pandemic were also reported. Another study from North India31 stressed the continuation of LDLT practices despite hurdles caused by the pandemic. An Indian report32 observed good outcomes of living donor kidney transplant (LDKT) conducted during the pandemic. A multicenter project33 reported less mortality in an early period of transplant and higher mortality in waitlisted patients with COVID-19. These evidences support continuing transplant in the COVID-19 pandemic with all safety measures if health care capacity is not overwhelmed.

Outcomes of SARS-CoV-2 infection in Solid-Organ Transplant in India Versus Other Areas of the World

Mortality rates among COVID-19-positive kidney transplant recipients (KTRs) were lower in India (11.6%) compared with the developed world, especially during the first wave, and lower compared with maintenance hemodialysis patients (13% to 38%), but significantly higher compared with the nonimmunosuppressed general population (1% to 3%) in India.34-36 The young age of SOT recipients might have contributed to less mortality in India compared with the developed world. The pandemic had affected all domains of health, as evidenced by a crosssectional study37 of 109 liver transplant recipients in India. The outcomes of liver transplant recipients were favorable in an Indian study.38 Outcomes of LDLT recipients with COVID-19 infection were reported in another North Indian study,39 with outcomes in patients who had recent kidney transplant shown to be favorable in a case series from Western India.40 This was one of the first few case series in world literature.

A small case series of 9 KTRs from Eastern India41 reported recovery in 100% of patients who acquired COVID-19. In a single-center study42 from North India of 20 cases, a large mortality rate of 25% was reported. Other reports from North India of 67 KTRs with COVID-19 showed 27% mortality overall with 100% mortality in ventilated patients43 and a mortality rate higher than the general population in 62 KTRs with COVID-19.44 A multicenter Indian study45 that compared COVID-19 KTRs versus nonimmunosuppressed patients during the first wave reported higher overall patient mortality rates (11.6%) in 250 KTRs than in nonimmunosuppressed patients (1%). This rate was less than that of the Western world during the first wave. A single-center study from a large Indian transplant center of 259 KTRs with COVID-19 demonstrated the changing clinical spectrum of COVID-19 with similar mortality between the 2 waves.46 In a report of the second wave from a South Indian center, 20 KTRs had good outcomes.47 A propensity-matched study48 of 1627 COVID-19 cases in which 179 were KTRs reported no difference in mortality among SOT recipients versus the general population. This was the first Indian report that conducted a head-to-head comparison in Indian ethnicity.

We reported for the first time in India the safety and feasibility of remdesivir49 and convalescent plasma component therapy50 for SOT patients with moderate to severe COVID-19. Because remdesivir was in the forefront as an anti-COVID-19 medicine, this work was an important one for widespread use of the drug, especially in India. Convalescent plasma component therapy was another potential anti-COVID-19 agent. Eventually, remdesivir and convalescent plasma component therapy51 showed no association with improved morbidity or mortality. Cytomegalovirus coinfection52 with COVID-19 was found to increase morbidity and mortality, showing the need for a holistic approach in the management of SOT. Rare coinfections in a liver transplant recipient with pulmonary aspergillosis, tuberculosis, and hemophagocytic lymphohistiocytosis was also reported.53

We reported the successful use of telemedicine for management of KTRs and donors in a single center.54 The use of telemedicine during the COVID-19 national lockdown and travel restrictions was useful in limiting the virus spread and in speeding the delivery of life-saving drugs such as immunosuppressives and could be a useful approach for future pandemics.55 Another report showed that use of telemedicine among pediatric nephrologists56 effectively managed care during the pandemic.

Data on pediatric SOTs from India remain scarce. In an Indian report57 of 7 pediatric SOT recipients with COVID-19, mortality was 10%. Another report58 showed complete recovery of a pediatric KTRs with COVID-19. In a pediatric liver transplant recipient,59 COVID-19 presented as hypoxia of unknown origin in the immediate transplant period.

Long-Term Status of COVID-19 in Solid-Organ Transplant Recipients

Long-term health issues of COVID-19 are an emerging issue in the world. There are limited reports on post- COVID-19 long-term follow-up in SOT recipients. A single-center report recorded favorable graft survival in KTRs with BK polyomavirus virus coinfections.60 The same center61 reported 1-year follow-up outcomes in KTRs with COVID-19, showing good clinical and psychosocial recovery results. A single-center report from Eastern India reported favorable follow-up of COVID-19 in KTRs. A subsequent report62 from a center in Western India, however, reported remarkable numbers of unrecovered or incompletely recovered acute kidney injuries in post-COVID-19 KTRs. In a follow-up study63 from Eastern India, similar results in 104 KTRs with COVID-19 were reported, with those with severe COVID-19 having high rates of residual abnormality, allograft dysfunction, and death. A study from Western India64 first reported the antibody dynamics following COVID-19 infection in KTRs with Indian ethnicity. In a first study of reinfection of COVID-19 among SOT recipients in India,65 reinfection resulted in mortality. A multicenter study66 reported that reoccurring SARS-CoV-2 infections resulted in 46% mortality, which was 4 times higher than the mortality rate during the first wave of the COVID-19 pandemic in SOT recipients (11%).

Although our limited resources did not allow for molecular diagnostics and typing, there was an anecdotal report67 of graft artery thrombosis in a KTR. Briefly, the COVID-19 long-term sequelae have been seen as a rare entity in SOT recipients, and transplant professionals have not postulated as much with these occurrences during the first wave versus during the second and third waves because of knowledge obtained from the first wave.

Evidence to Support Transplant With Donors With History of or With Ongoing COVID-19 Infection

Because living donation practices have been the mainstay of SOT in India, it was imperative to conclude the definitive evidence for safety of living donors who donated after recovery from COVID-19. In a multicenter study68 of a large cohort of LDKT recipients who had COVID-19- recovered donors (n = 31), although the follow-up was relatively short, an absence of any occult complications and 100% patient and graft survival showed the safety of such transplants. In a case report from India69 of a deceased donor with COVID-19 who died after terminal lung damage from COVID-19, lung transplant was avoided but kidney transplant was performed. The successful outcomes with both kidneys were encouraging, showing that donors who have recently died from COVID-19 can be potential deceased donors with careful selection. A multicenter report from South India70 documented 9 living donor hepatectomies after COVID-19 illness, and a comprehensive review71 identified 25 such reports, showing that SOT performed in COVID-19-recovered donors was safe. Interestingly, some donors showed positivity in their real-time polymerase chain reaction tests at the time of donation; however, outcomes were not inferior. The shortterm follow-up of living donors after donation was mostly uneventful. Still, further long-term data on such donations are needed.

Complications of Recipients With COVID-19 After Transplant: Answering the Puzzle With Precision

An anecdotal study72 reported recurrent hepatic thrombosis after liver transplant in a patient with mild COVID-19 infection, raising concerns about the risks with a postulated hypercoagulability state after COVID-19 infections. A small bowel transplant following gangrene after COVID-19 in a child was first reported from India.73 An initial report of successful LDKT from India marked the safety of LDKT following COVID-19 illness.74 A South Indian center75 reported the first case of liver transplant after COVID-19 illness. A liver transplant76 was performed successfully in which the candidate recently recovered from COVID-19, breaking the threshold of a minimum 28-day asymptomatic period before surgery. To investigate the ideal strategy, we conducted a nationwide report77 in which data from 75 KTRs who underwent LDKT were analyzed. The encouraging report showed 100% patient and graft survival. Prerequisites reported involved an asymptomatic period of at least 28 days, social distancing between donor and recipient for 14 days, no residual radiological abnormality, and at least 2 negative polymerase chain reaction SARS-CoV-2 tests.

Because of shorter follow-up and a smaller number of severe COVID-19 cases, we confirmed the conclusions and safety of the report with another nationwide collaboration. A study of 372 COVID-19-recovered transplant candidates and the largest cohort of post-COVID-19 kidney donors who underwent LDKT,78 with the largest median followup time of 241 days, reported on the safety of high-risk kidney transplant, where both the donor and recipient had COVID-19 history or were ABO-incompatible or sensitized. An important observation was no tailoring of induction or maintenance immunosuppression irrespective of the time gap from infection to transplant or severity of COVID-19 infection.

Other data on excellent outcomes of liver transplant in COVID-19-recovered patients have been reported from India.79 A recent South Indian study reported acceptable outcomes in 51 living donor liver transplant recipients who had recovered from COVID-19.79 Another study reported favorable outcomes in the largest cohort of deceased donor liver transplant of COVID-19-recovered candidates.80 A recent review81 concluded that patient and graft survival rates in COVID-19-recovered or even positive patients who underwent SOT were acceptable. Clinical symptoms at the time of surgery, cycle threshold value, radiological abnormalities, time from a positive to negative COVID-19 test, and the immune response of the recipient at the time of infection are parameters that decide the appropriate timing of transplant.

Lung transplant as a rescue after COVID-19 pulmonary sequelae remains an important issue. One such report was published by an Indian center82; in multinational data,83 with contributions from a South Indian center, early excellent outcomes of lung transplant following pulmonary sequelae were reported. A daunting question in this scenario was the optimal timing at which the decision to proceed with lung transplant. This report was streamlined by the protocol and timing, which guided many transplant centers across the world. In a recent report84 of a large cohort of lung transplant recipients following COVID-19, there was 100% patient survival.

COVID-19-Associated Mucormycosis in Solid-Organ Transplant: A Double Whammy Amid the Pandemic

During the second wave of the pandemic in India, the emergence of COVID-19-associated mucormycosis (CAM) broke the backbone of medical services, and India became the hub of CAM, as the bulk of the reports came from India. The definition, risk factors, diagnosis, and treatment were initially skeptical, but a consensus was soon formed.85 From a historical point of view, patients with SOT remain at high risk of fungal infections, and CAM was also a threat to SOT. One of the first such reports in the world literature was from India.86 Another report87 of disseminated CAM in KTR, which ended in mortality, was also published. In a large single-center case series of 11 cases of CAM in 157 KTRs with COVID-19, 27% mortality was reported,88 with diabetes, high neutrophil-to-lymphocyte ratio, and lymphopenia being risk factors for acquiring CAM. A study from a North Indian transplant center89 reported similar mortality with a similar phenotype. In a multicenter study (n = 18),90 representing the largest cohort of CAM in KTRs, the incidence was 4.4% (61 of 1382 COVID-19 KTRs) and the mortality rate was 26.2%, with obesity and high-flow oxygen requirement being risk factors for mortality.

Mortality is high in pulmonary mucormycosis when compared with other infections. This shows the added damage done by COVID-19 pneumonia, as well as issues with late diagnosis and the difficulty in implementation of multidisciplinary management during the pandemic. An isolated case of allograft mucormycosis in a KTR who succumbed to death was also reported.91 Allograft CAM with bacterial pyelonephritis (E. coli) resulted in death in another KTR,92 and CAM with mycotic aneurysm was reported in a separate KTR.93 The emergence of opportunistic infections should be suspected, and timely management should be implemented during pandemics. Uncontrolled diabetes, overuse of steroids, iron therapy, broad-spectrum antibiotics, zinc in multivitamins, and reuse of masks were possible contributing factors for mucormycosis epidemics within the COVID-19 pandemic during the second wave in India.94

Indian Ethnicity Data for COVID-19 Vaccination in Solid-Organ Transplant

The first case series95 of breakthrough COVID-19 infections following the COVISHEILD vaccine in SOT recipients was reported from India. Breakthrough infections among patients on the waitlist with the Oxford vaccine were also reported first by an Indian center.96 Breakthrough infections were also reported among patients on the waitlist and liver transplant recipients from India.97 These reports all underscored the need for continued COVID-19 vigilance even after vaccination in these highrisk patients, especially in high transmission states. Few data are available on vaccine immunogenicity in SOT. In a North Indian study,98 COVISHIELD and COVAXIN together were studied in KTRs, and it was reported that, although the humoral response was developed in patients, the magnitude of response was lesser than the seroresponse following COVID-19 infection. In a meta-analysis of 112 studies, the humoral response rate after the primary series of vaccinations was recorded as 40%. Currently, a booster dose is in practice, and the Western world has moved up to the fourth or fifth dose. However, in Indian centers, booster dosing in SOT is not mandatory, and these practices are for research purposes. The presence of VITT was a relatively newer entity in the pandemic, which was mostly associated with the Oxford vaccine, and a report on organs from VITT donors was published recently.99 There are numerous ethical aspects of vaccination,100 which extend from vaccination of health care workers to family members of transplant candidates. In an international survey,101 which reported the real-world practices on organ donation, most nations are less keen to accept organs from unvaccinated donors and also from donors with COVID-19 infection who are asymptomatic. Most transplant centers are in favor of vaccinating candidates before they receive an organ but do not withhold from the list if not vaccinated. This is true in India, where there is no withdrawal from the waitlist if the candidate is not vaccinated. Research investigations on COVID-19 vaccines are still needed.102

Conclusions

There is a global spectrum of outcomes of SOT and COVID-19, with lesser mortality due to younger age of SOT recipients or higher risk when there are opportunistic or secondary infections. The higher mortality rate in SOT recipients who require ventilation shows the important need for precision medicine, the need for higher advanced medical facilities, and the need for improved care in many regions of India. Our report suggested that transplant from carefully selected COVID-19-recovered donors and patients may be feasible and safe, at least in the short-term follow-up. However, data on vaccines are sparse and still accumulating, with further research needed. Continued research is needed on vaccine efficacy, booster doses, and long term follow-up sequelae.


References:

  1. Aubert O, Yoo D, Zielinski D, et al. COVID-19 pandemic and worldwide organ transplantation: a population-based study. Lancet Public Health. 2021;6(10):e709-e719. doi:10.1016/S2468-2667(21)00200-0
    CrossRef - PubMed
  2. Ministry of Health and Family Welfare. Government of India. Accessed April 16, 2022. https://www.mohfw.gov.in/
    CrossRef - PubMed
  3. Jothimani D, Daniel H, Danielraj S, Ramachandran H, Rela M. COVID-19 lockdown: impact on liver transplant recipients-a single centre survey. J Assoc Physicians India. 2020;68(8):96.
    CrossRef - PubMed
  4. Menon J, Shanmugam N, Patel K, Hakeem A, Reddy MS, Rela M. Awareness and concerns about novel coronavirus disease 2019 (COVID-19) among parents of pediatric liver transplant recipients. Pediatr Transplant. 2020;24(8):e13805. doi:10.1111/petr.13805
    CrossRef - PubMed
  5. Patel MP, Kute VB, Agarwal SK; COVID-19 Working Group of Indian Society of Nephrology. “Infodemic” COVID 19: more pandemic than the virus. Indian J Nephrol. 2020;30(3):188-191. doi:10.4103/ijn.IJN_216_20
    CrossRef - PubMed
  6. Kute V, Guleria S, Prakash J, et al. NOTTO Transplant Specific Guidelines with reference to COVID-19. Indian J Nephrol. 2020;30(4):215-220. doi:10.4103/ijn.IJN_299_20
    CrossRef - PubMed
  7. Kute V, Varugese S, Prasad N, Shroff S, Agarwal SK; COVID-19 Working Group of Indian Society of Nephrology. Renal Transplant Guidelines with reference to COVID-19 infection. Indian J Nephrol. 2020;30(3):176-178. doi:10.4103/ijn.IJN_221_20
    CrossRef - PubMed
  8. Kute VB, Agarwal SK, Prakash J, et al. NOTTO COVID-19 Vaccine Guidelines for Transplant Recipients. Indian J Nephrol. 2021;31(2):89-91. doi:10.4103/ijn.IJN_64_21
    CrossRef - PubMed
  9. Kute V, Meshram HS, Sharma A, et al. Update on coronavirus 2019 vaccine guidelines for transplant recipients. Transplant Proc. 2021;S0041-1345(21)00683-7. doi:10.1016/j.transproceed.2021.09.007
    CrossRef - PubMed
  10. Kute VB, Asthana S, Gupta S, et al. NOTTO guidelines for vaccine-induced thrombotic thrombocytopenia in organ donation and transplantation. Indian J Transplant. 2022;16(1):3-7. doi:10.4103/ijot.ijot_135_21
    CrossRef - PubMed
  11. Kute VB, Guleria S, Bhalla AK, et al. ISOT consensus statement for the kidney transplant recipient and living donor with a previous diagnosis of COVID-19. Indian J Transplant. 2021;15(2):131-133. doi:10.4103/ijot.ijot_26_21
    CrossRef - PubMed
  12. Gupta S, Sudhindran S, Saraf N, et al. Liver Transplant Society of India guidelines for liver transplant during COVID-19 times. J Clin Exp Hepatol. 2022;12(1):180-185. doi:10.1016/j.jceh.2021.08.012
    CrossRef - PubMed
  13. Varma S, Pandey Y, Chikkala BR, et al. Protocol to ensure continued pediatric liver transplantation service during the COVID pandemic and the encouraging outcomes. Pediatr Transplant. 2021;25(3):e13991. doi:10.1111/petr.13991
    CrossRef - PubMed
  14. Krishna Gokhale A, Balakrishnan K, Punnen J, et al. Recommendations of the INSHLT task force for thoracic organ transplant during COVID-19 pandemic in India. J Practice Cardiovasc Sci. 2020;6(2):108
    CrossRef - PubMed
  15. Asthana S, Kute V, Shah U, et al. Consensus statement on organ donation from COVID-positive deceased donors-Indian Society of Organ Transplantation, Liver Transplant Society of India and Indian Society for Heart and Lung Transplantation. Indian J Transplant 2022;16:8-16. doi:10.4103/ijot.ijot_29_22
    CrossRef - PubMed
  16. Hakeem AR, Padmanaban H, Karthikeyan S, et al. Awareness and concerns among adult liver transplant recipients in the current pandemic caused by novel coronavirus (COVID-19): strategies to safeguard a high-risk population. J Clin Exp Hepatol. 2020;10(6):540-547. doi:10.1016/j.jceh.2020.06.001
    CrossRef - PubMed
  17. Lobo V, Khanna U, Rajapurkar M, et al. Guidelines for dialysis with reference to COVID-19. Indian J Nephrol. 2020;30(3):166-170. doi:10.4103/ijn.IJN_166_20
    CrossRef - PubMed
  18. Kute VB, Meshram HS, Mahillo B, Dominguez-Gil B. Transplantation in India and China during the COVID-19 pandemic. Lancet Public Health. 2022;7(1):e12. doi:10.1016/S2468-2667(21)00280-2
    CrossRef - PubMed
  19. Kute VB, Tullius SG, Rane H, Chauhan S, Mishra V, Meshram HS. Global impact of the COVID-19 pandemic on solid organ transplant. Transplant Proc. 2022;S0041-1345(22)00132-4. doi:10.1016/j.transproceed.2022.02.009
    CrossRef - PubMed
  20. Kute VB, Ramesh V, Rela M. On the way to self-sufficiency: improving deceased organ donation in India. Transplantation. 2021;105(8):1625-1630. doi:10.1097/TP.0000000000003677
    CrossRef - PubMed
  21. Kute V, Ramesh V, Shroff S, et al. Benefit to few versus risk to many: an ethical dilemma during coronavirus disease 2019 pandemic for deceased-donor organ transplant in a resource-limited developing country. Exp Clin Transplant. 2021;19(1):1-7. doi:10.6002/ect.2020.0134
    CrossRef - PubMed
  22. Reddy MS, Hakeem AR, Klair T, et al. Trinational study exploring the early impact of the COVID-19 pandemic on organ donation and liver transplantation at national and unit levels. Transplantation. 2020;104(11):2234-2243. doi:10.1097/TP.0000000000003416
    CrossRef - PubMed
  23. Kute VB, Gupta A, Patel HV, et al. The impact of COVID-19 pandemic on nephrology and transplant services and clinical training in India. Exp Clin Transplant. 2021;19(7):651-658. doi:10.6002/ect.2021.0018
    CrossRef - PubMed
  24. Meshram HS, Kute VB, Swarnalatha G, et al. Effect of coronavirus disease 2019 on transplantation and nephrology in India: a nationwide report from India. Transplant Proc. 2021;S0041-1345(21)00684-9. doi:10.1016/j.transproceed.2021.09.008
    CrossRef - PubMed
  25. Varma S, Pandey Y, Chikkala BR, et al. Protocol to ensure continued pediatric liver transplantation service during the COVID pandemic and the encouraging outcomes. Pediatr Transplant. 2021;25(3):e13991. doi:10.1111/petr.13991
    CrossRef - PubMed
  26. Reddy MS, Menon J, Hakeem AR, et al. How can we reduce the impact of COVID-19 pandemic on timely access to liver transplantation in children? Hepatol Int. 2021;15(1):215-216. doi:10.1007/s12072-020-10128-9
    CrossRef - PubMed
  27. Menon J, Hakeem AR, Rammohan A, et al. Living donor liver transplantation during the COVID-19 pandemic: a serendipitous silver lining! Transplantation. 2021;105(2):e20-e21. doi:10.1097/TP.0000000000003574
    CrossRef - PubMed
  28. Varghese J, Malleeswaran S, Patcha RV, et al. A multicentric experience on living donor liver transplantation in coronavirus disease 2019 hotspots in India. Liver Transpl. 2021;27(9):1334-1338. doi:10.1002/lt.25957
    CrossRef - PubMed
  29. Verma S, Agarwal S, Chikkala BR, et al. Living donor liver transplants for sick recipients during COVID-19 pandemic-an experience from a tertiary center in India. Am J Transplant. 2020;20(11):3257-3258. doi:10.1111/ajt.16102
    CrossRef - PubMed



  30. Soin AS, Choudhary NS, Yadav SK, et al. Restructuring living-donor liver transplantation at a high-volume center during the COVID-19 pandemic. J Clin Exp Hepatol. 2021;11(4):418-423. doi:10.1016/j.jceh.2020.09.009
    CrossRef - PubMed
  31. Singhal A, Sahota GS, Srivastava P, et al. Living donor liver transplantation during the COVID-19 pandemic: “elective” but “necessary.” Transplantation. 2020;104(12):e351-e353. doi:10.1097/TP.0000000000003449
    CrossRef - PubMed
  32. Jha PK, Yadav DK, Siddini V, et al. A retrospective multi-center experience of renal transplants from India during COVID-19 pandemic. Clin Transplant. 2021;35(10):e14423. doi:10.1111/ctr.14423
    CrossRef - PubMed
  33. Meshram HS, Kute VB, Patel HV, et al. Is early COVID-19 in kidney transplant recipients concerning enough to halt transplantation? A multicenter comparative analysis from India. Transplant Proc. 2021;53(8):2468-2475. doi:10.1016/j.transproceed.2021.08.034
    CrossRef - PubMed
  34. Prasad N, Behera MR, Bhatt M, et al. Outcomes of symptomatic coronavirus disease 19 in maintenance hemodialysis patient in India. Semin Dial. 2021;34(5):360-367. doi:10.1111/sdi.13000
    CrossRef - PubMed
  35. Trivedi M, Shingada A, Shah M, Khanna U, Karnik ND, Ramachandran R. Impact of COVID-19 on maintenance haemodialysis patients: the Indian scenario. Nephrology (Carlton). 2020;25(12):929-932. doi:10.1111/nep.13760
    CrossRef - PubMed
  36. Banerjee S, Patel HV, Engineer DP, Gupta V, Patel H, Gupta A, Shah PR, Kute VB. COVID-19 in hemodialysis patients: experience from a Western Indian center. Indian J Nephrol. E-pub ahead of print. https://www.indianjnephrol.org/preprintarticle.asp?id=334445
    CrossRef - PubMed
  37. Choudhury A, Varshney M, Sahoo B, et al. Impact of covid-19 pandemic on quality of life and psychosocial difficulties among liver transplant recipients. J Family Med Prim Care. 2022;11(2):744-750. doi:10.4103/jfmpc.jfmpc_1798_21
    CrossRef - PubMed
  38. Choudhury A, Reddy GS, Venishetty S, et al. COVID-19 in liver transplant recipients - a series with successful recovery. J Clin Transl Hepatol. 2020;8(4):467-473. doi:10.14218/JCTH.2020.00061
    CrossRef - PubMed
  39. Dhampalwar S, Saigal S, Choudhary N, et al. Outcomes of coronavirus disease 2019 in living donor liver transplant recipients. Liver Transpl. 2020;26(12):1665-1666. doi:10.1002/lt.25909
    CrossRef - PubMed
  40. Shingare A, Bahadur MM, Raina S. COVID-19 in recent kidney transplant recipients. Am J Transplant. 2020;20(11):3206-3209. doi:10.1111/ajt.16120
    CrossRef - PubMed
  41. Krishna A, Singh PP, Vardhan H, Kumar O. Better outcome of coronavirus disease 2019 infection in kidney transplant recipients: a case series from Eastern India. Saudi J Kidney Dis Transpl. 2021;32(3):875-879. doi:10.4103/1319-2442.336787
    CrossRef - PubMed
  42. Bhandari G, Tiwari V, Gupta A, et al. COVID-19 infection in renal transplant patients: early report from India. Indian J Nephrol. 2021;31(3):271-275. doi:10.4103/ijn.IJN_323_20
    CrossRef - PubMed
  43. Jasuja S, Sagar G, Bahl A, Verma S. COVID-19 infection clinical profile, management, outcome, and antibody response in kidney transplant recipients: a single centre experience. Int J Nephrol. 2021;2021:3129411. doi:10.1155/2021/3129411
    CrossRef - PubMed
  44. Godara S, Saraf KK, Sadasukhi TC, et al. COVID-19 infection in kidney transplant recipients: a single centre study from Northern India. Indian J Nephrol. 2021;31(6):531-535. doi:10.4103/ijn.IJN_571_20
    CrossRef - PubMed
  45. Kute VB, Bhalla AK, Guleria S, et al. Clinical profile and outcome of COVID-19 in 250 kidney transplant recipients: a multicenter cohort study from India. Transplantation. 2021;105(4):851-860. doi:10.1097/TP.0000000000003593
    CrossRef - PubMed
  46. Kute VB, Meshram HS, Navadiya VV, et al. Consequences of the first and second COVID-19 wave on kidney transplant recipients at a large Indian transplant centre. Nephrology (Carlton). 2022;27(2):195-207. doi:10.1111/nep.13961
    CrossRef - PubMed
  47. Tatapudi RR, Kopparti VR, Poosapati A, Metta S, Gongada AR, Vedulla B. SARS-CoV-2 infection in kidney transplant recipients: a single-centre study of 20 cases from India. Int J Nephrol. 2021;2021:2243095. doi:10.1155/2021/2243095
    CrossRef - PubMed
  48. Kute VB, Meshram HS, Chauhan S, et al. A propensity-matched analysis of COVID-19 in kidney transplant recipients compared with non-kidney transplant patients: a single-center report from India. Exp Clin Transplant. 2021;19(12):1263-1270. doi:10.6002/ect.2021.0438
    CrossRef - PubMed
  49. Meshram HS, Kute VB, Patel H, et al. Feasibility and safety of remdesivir in SARS-CoV2 infected renal transplant recipients: a retrospective cohort from a developing nation. Transpl Infect Dis. 2021;23(4):e13629. doi:10.1111/tid.13629
    CrossRef - PubMed
  50. Meshram HS, Kute VB, Patel H, et al. Feasibility and safety of remdesivir in SARS-CoV2 infected renal transplant recipients: a retrospective cohort from a developing nation. Transpl Infect Dis. 2021;23(4):e13629. doi:10.1111/tid.13629
    CrossRef - PubMed
  51. Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020;371:m3939. doi:10.1136/bmj.m3939
    CrossRef - PubMed
  52. Meshram HS, Kute VB, Patel H, Banerjee S, Desai S, Chauhan S. Cytomegalovirus and severe acute respiratory syndrome coronavirus 2 co-infection in renal transplants: a retrospective study from a single center. Saudi J Kidney Dis Transpl. 2021;32(4):929-938. doi:10.4103/1319-2442.338304
    CrossRef - PubMed
  53. Gandotra A, Mehtani R, Premkumar M, et al. Invasive pulmonary aspergillosis and tuberculosis complicated by hemophagocytic lymphohistiocytosis - sequelae of COVID-19 in a liver transplant recipient. J Clin Exp Hepatol. 2022;12(3):1007-1011. doi:10.1016/j.jceh.2021.12.002
    CrossRef - PubMed
  54. Kute VB, Gupta V, Patel HV, et al. Role of telemedicine in kidney transplant recipient in COVID 19 era. Indian J Transplant. 2022;16:107-112.
    CrossRef - PubMed
  55. Venkatesh U, Aravind GP, Velmurugan AA. Telemedicine practice guidelines in India: global implications in the wake of the COVID-19 pandemic. World Med Health Policy. 2022;10.1002/wmh3.497. doi:10.1002/wmh3.497
    CrossRef - PubMed
  56. Raina R, Nair N, Yap HK, et al. Survey of telemedicine by pediatric nephrologists during the COVID-19 pandemic. Kidney Int Rep. 2021;6(9):2316-2322. doi:10.1016/j.ekir.2021.06.026
    CrossRef - PubMed
  57. Meshram A, Vala KB, Saha A, Patel HV, Kute V, Gera D. Coronavirus disease-2019 in children with primary kidney disease: a case series. Saudi J Kidney Dis Transpl. 2021;32(1):218-222. doi:10.4103/1319-2442.318527
    CrossRef - PubMed
  58. Tatapudi RR, Kopparti VR, Poosapati A, Metta S, Palli V, Vedulla B. Severe acute respiratory syndrome corona virus-2 infection in a pediatric kidney transplant recipient: a case report from India. Case Rep Nephrol Dial. 2021;11(3):367-373. doi:10.1159/000520558
    CrossRef - PubMed
  59. Sindwani G, Abhinaya SV, Arora MK, Pamecha V, Lal BB. COVID-19 infection in a child following liver transplantation. Anaesth Rep. 2021;9(2):e12139. doi:10.1002/anr3.12139
    CrossRef - PubMed
  60. Meshram HS, Kute VB, Chauhan S. BK polyomavirus infection following COVID-19 infection in renal transplant recipients: a single-center experience. Kidney Res Clin Pract. 2021;40(3):496-500. doi:10.23876/j.krcp.21.082
    CrossRef - PubMed
  61. Chauhan S, Meshram HS, Kute V, Patel H, Desai S, Dave R. Long-term follow-up of SARS-CoV-2 recovered renal transplant recipients: a single-center experience from India. Transpl Infect Dis. 2021;23(6):e13735. doi:10.1111/tid.13735
    CrossRef - PubMed
  62. Bajpai D, Deb S, Bose S, et al. Recovery of kidney function after AKI because of COVID-19 in kidney transplant recipients. Transpl Int. 2021;34(6):1074-1082. doi:10.1111/tri.13886
    CrossRef - PubMed
  63. Meyyappan J, Prasad N, Kushwaha R, et al. Health-related quality of life score and outcomes in living donor renal transplant recipients with COVID-19. Exp Clin Transplant. 2022;20(1):42-51. doi:10.6002/ect.2021.0332
    CrossRef - PubMed
  64. Bajpai D, Shah D, Bose S, et al. Development and longevity of antibodies against SARS-CoV-2 in kidney transplant recipients after symptomatic COVID-19. Transpl Infect Dis. 2021;23(4):e13646. doi:10.1111/tid.13646
    CrossRef - PubMed
  65. Kute VB, Meshram HS, Patel HV, et al. Fatal outcome subsequent to reoccurring SARS-CoV2 infection in a kidney transplant recipient. Clin Transplant. 2021;35(9):e14383. doi:10.1111/ctr.14383
    CrossRef - PubMed
  66. Kute VB, Hegde U, Das P, et al. A multicenter cohort study of Indian centers on reoccurring SARS-CoV-2 infections in kidney transplant recipients. Exp Clin Transplant. 2021;19(10):1023-1031. doi:10.6002/ect.2021.0284
    CrossRef - PubMed
  67. Varma PP, Kute VB, Bajpai G. Renal graft artery thrombosis following COVID-19 infection. Nephrology (Carlton). 2021;26(11):932-933. doi:10.1111/nep.13919
    CrossRef - PubMed
  68. Kute VB, Godara S, Guleria S, et al. Is it safe to be transplanted from living donors who recovered from COVID-19? Experience of 31 kidney transplants in a multicenter cohort study from India. Transplantation. 2021;105(4):842-850. doi:10.1097/TP.0000000000003609
    CrossRef - PubMed
  69. Meshram HS, Kute VB, Patel H, Desai S, Chauhan S, Dave RB. A case report of successful kidney transplantation from a deceased donor with terminal COVID-19-related lung damage: ongoing dilemma between discarding and accepting organs in COVID-19 era! Transpl Infect Dis. 2021;23(5):e13683. doi:10.1111/tid.13683
    CrossRef - PubMed
  70. Malleeswaran S, Mohanka R, Yalakanti RB, et al. Living donor hepatectomy after proven SARS-CoV-2 infection: first report of 9 cases from 3 centers. Transplantation. 2021;105(7):e70-e71. doi:10.1097/TP.0000000000003750
    CrossRef - PubMed
  71. Kute VB, Fleetwood VA, Meshram HS, Guenette A, Lentine KL. Use of organs from SARS-CoV-2 infected donors: is it safe? A contemporary review. Curr Transplant Rep. 2021;8(4):281-292. doi:10.1007/s40472-021-00343-0
    CrossRef - PubMed
  72. Raj A, Shankar V, Singhal S, et al. Recurrent hepatic artery thrombosis following living donor liver transplant as sequelae of SARS-CoV-2 infection-a case report. SN Compr Clin Med. 2021;3(12):2629-2634. doi:10.1007/s42399-021-01076-y
    CrossRef - PubMed
  73. Chaubal G, Hatimi H, Nanavati A, et al. Pediatric living donor intestine transplant following an atypical complication of COVID-19: a unique case report from India. Am J Transplant. 2021;21(12):4079-4083. doi:10.1111/ajt.16798
    CrossRef - PubMed



  74. Kanchi P, Sambandam S, Siddhan R, Soundappan S, Vaseekaran VP, Gupta A. Successful kidney transplantation after COVID-19 infection in two cases. Nefrologia (Engl Ed). 2021;42(2):217-219. doi:10.1016/j.nefro.2020.12.004
    CrossRef - PubMed
  75. Kulkarni AV, Parthasarathy K, Kumar P, et al. Early liver transplantation after COVID-19 infection: the first report. Am J Transplant. 2021;21(6):2279-2284. doi:10.1111/ajt.16509
    CrossRef - PubMed
  76. Raut V, Sonavane A, Shah K, et al. Successful liver transplantation immediately after recovery from COVID-19 in a highly endemic area. Transpl Int. 2021;34(2):376-377. doi:10.1111/tri.13790
    CrossRef - PubMed
  77. Kute VB, Ray DS, Yadav DK, et al. A multicenter cohort study from India of 75 kidney transplants in recipients recovered after COVID-19. Transplantation. 2021;105(7):1423-1432. doi:10.1097/TP.0000000000003740
    CrossRef - PubMed
  78. Kute VB, Ray DS, Aziz F, et al. Management strategies and outcomes in renal transplant recipients recovering from COVID-19: a retrospective, multicentre, cohort study. EClinicalMedicine. 2022;101359. doi:10.1016/j.eclinm.2022.101359
    CrossRef - PubMed
  79. Rajakumar A, Paulin S, Velusamy P, et al. Outcomes of liver transplantation in recipients with previous COVID-19 infection. Liver Transpl. 2022;10.1002/lt.26476. doi:10.1002/lt.26476
    CrossRef - PubMed
  80. Natori Y, Anjan S, Martin EF, et al. When is it safe to perform abdominal transplantation in patients with prior SARS-CoV-2 infection: a case series. Clin Transplant. 2021;35(12):e14370. doi:10.1111/ctr.14370
    CrossRef - PubMed
  81. Kute V, Meshram HS, Fleetwood VA, Chauhan S, Lentine KL. Solid organ transplantation in SARS-CoV-2 recovered transplant candidates: a comprehensive review of recent literature. Curr Transplant Rep. 2022; 9(2):95-107. doi:10.1007/s40472-022-00362-5
    CrossRef - PubMed
  82. Gogia P, Attawar S, Singh V, et al. Lung transplantation for post-COVID-19 pulmonary fibrosis. Respirol Case Rep. 2021;9(11):e0862. doi:10.1002/rcr2.862
    CrossRef - PubMed
  83. Bharat A, Machuca TN, Querrey M, et al. Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries. Lancet Respir Med. 2021;9(5):487-497. doi:10.1016/S2213-2600(21)00077-1
    CrossRef - PubMed
  84. Kurihara C, Manerikar A, Querrey M, et al. Clinical characteristics and outcomes of patients with COVID-19-associated acute respiratory distress syndrome who underwent lung transplant. JAMA. 2022;327(7):652-661. doi:10.1001/jama.2022.0204
    CrossRef - PubMed
  85. Muthu V, Agarwal R, Patel A, et al. Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India. Lancet Infect Dis. 2022;S1473-3099(22)00124-4. doi:10.1016/S1473-3099(22)00124-4
    CrossRef - PubMed
  86. Meshram HS, Kute VB, Chauhan S, Desai S. Mucormycosis in post-COVID-19 renal transplant patients: a lethal complication in follow-up. Transpl Infect Dis. 2021;23(4):e13663. doi:10.1111/tid.13663
    CrossRef - PubMed
  87. Meshram HS, Kumar D, Kute VB. Rare and unusual follow-up sequelae of coronavirus disease 2019: splenic mucormycosis in a renal transplant recipient. Transplant Proc. 2021;S0041-1345(21)00686-2. doi:10.1016/j.transproceed.2021.09.010
    CrossRef - PubMed
  88. Meshram HS, Kute VB, Chauhan S, et al. Mucormycosis as SARS-CoV2 sequelae in kidney transplant recipients: a single-center experience from India. Int Urol Nephrol. 2021;1-11. doi:10.1007/s11255-021-03057-5
    CrossRef - PubMed
  89. Bansal SB, Rana A, Babras M, et al. Risk factors and outcomes of COVID associated mucormycosis in kidney transplant recipients. Transpl Infect Dis. 2022;24(2):e13777. doi:10.1111/tid.13777
    CrossRef - PubMed
  90. Meshram HS, Kute VB, Yadav DK, et al. Impact of COVID-19-associated mucormycosis in kidney transplant recipients: a multicenter cohort study. Transplant Direct. 2021;8(1):e1255. doi:10.1097/TXD.0000000000001255
    CrossRef - PubMed
  91. Sethia RK, Charag AH. A case of isolated unilateral renal mucormycosis post COVID-19 pneumonia with fatal outcome. Urol Case Rep. 2022;43:102061. doi:10.1016/j.eucr.2022.102061
    CrossRef - PubMed
  92. Chandra A, Rao S N, Malhotra KP. Fatal allograft mucormycosis complicating severe COVID-19 infection and bacterial pyelonephritis. Transpl Infect Dis. 2022;24(2):e13793. doi:10.1111/tid.13793
    CrossRef - PubMed
  93. Dantis K, Rathore V, Kashyap NK, Gupta N, De S, Singha SK. SARS-CoV-2 sequel: pulmonary mucormycosis with a mycotic aneurysm in a transplant recipient. Tuberc Respir Dis (Seoul). 2021;84(4):335-337. doi:10.4046/trd.2021.0098
    CrossRef - PubMed
  94. Patel A, Agarwal R, Rudramurthy SM, et al. Multicenter epidemiologic study of coronavirus disease-associated mucormycosis, India. Emerg Infect Dis. 2021;27(9):2349-2359. doi:10.3201/eid2709.210934
    CrossRef - PubMed
  95. Meshram HS, Kute VB, Shah N, et al. COVID-19 in kidney transplant recipients vaccinated with Oxford-AstraZeneca COVID-19 vaccine (Covishield): a single-center experience from India. Transplantation. 2021;105(9):e100-e103. doi:10.1097/TP.0000000000003835
    CrossRef - PubMed
  96. Chauhan S, Meshram HS, Kute V, et al. SARS-CoV-2 infection in chronic kidney disease patients vaccinated with Oxford/AstraZeneca COVID-19 vaccine: initial Indian experience. Clin Kidney J. 2021;14(10):2263-2265. doi:10.1093/ckj/sfab108
    CrossRef - PubMed
  97. Moon AM, Webb GJ, García-Juárez I, et al. SARS-CoV-2 infections among patients with liver disease and liver transplantation who received COVID-19 vaccination. Hepatol Commun. 2022;6(4):889-897. doi:10.1002/hep4.1853
    CrossRef - PubMed
  98. Prasad N, Yadav B, Singh M, et al. Humoral immune response of SARS-CoV-2 infection and anti-SARS-CoV-2 vaccination in renal transplant recipients. Vaccines (Basel). 2022;10(3):385. doi:10.3390/vaccines10030385
    CrossRef - PubMed
  99. Guditi S, Setty G, Verma M, et al. Vaccine-induced thrombotic thrombocytopenia due to coronavirus disease 2019 vaccine from a deceased donor: a case report. Transplant Proc. 2021;S0041-1345(21)00794-6. doi:10.1016/j.transproceed.2021.11.002
    CrossRef - PubMed
  100. Kates OS, Stock PG, Ison MG, et al. Ethical review of COVID-19 vaccination requirements for transplant center staff and patients. Am J Transplant. 2022;22(2):371-380. doi:10.1111/ajt.16878
    CrossRef - PubMed
  101. Caliskan Y, Axelrod D, Guenette A, et al. COVID-19 vaccination timing and kidney transplant waitlist management: an international perspective. Transpl Infect Dis. 2022;24(1):e13763. doi:10.1111/tid.13763
    CrossRef - PubMed
  102. Kute VB, Meshram HS, Chauhan S, et al. COVID-19 pandemic research opportunities in India: what the pandemic is teaching us about transplantation. Exp Clin Transplant. 2022;20(Suppl 1):10-16. doi:10.6002/ect.MESOT2021.L18
    CrossRef - PubMed


Volume : 20
Issue : 8
Pages : 32 - 42
DOI : 10.6002/ect.DonorSymp.2022.L21


PDF VIEW [137] KB.
FULL PDF VIEW

From the 1Department of Nephrology and Transplantation, Institute of Kidney Diseases and Research Center, Dr. HL Trivedi Institute of Transplantation Sciences (IKDRCITS), Ahmedabad, India; the 2Institute of Liver Disease & Transplantation, Dr. Rela Institute & Medical Centre, Chancellor, Bharath Institute of Higher Education & Research, Chennai, India; the 3Department of Nephrology, MGM Healthcare, Chennai, Tamil Nadu, India; the 4Department of Nephrology, Fortis Group of Hospitals, New Delhi, India; and the 5Department of Nephrology, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi, India
Acknowledgements: The authors have not received any funding or grants in support of the presented research or for the preparation of this work and have no declarations of potential conflicts of interest.
Corresponding author: Vivek B. Kute, Department of Nephrology and Transplantation, Institute of Kidney Disease and Research Center, Institute of Transplantation Sciences, Ahmedabad, 380016 Gujarat, India
E-mail: drvivekkute@rediffmail.com